Brind.
  1. Inspire's therapy received FDA approval on August 27, 2025, and Rick Buchholz was serving as Chief Financial Officer.

Piper Sandler lowered its price target for Inspire after the company released its Q2 2025 financial results.

1 report, 1 independent Updated Aug 7
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Piper Sandler lowered its price target for Inspire after the company released its Q2 2025 financial results.

Who's involved

What this event is mainly about
InspirePiper Sandler Companies

Keep exploring

Part of

Inspire's therapy received FDA approval on August 27, 2025, and Rick Buchholz was serving as Chief Financial Officer. All 2 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • Insider MonkeyPiper Sandler Lowers PT on Inspire Medical Systems (INSP) to $150 From $233 Inspire Medical Systems, Inc. (NYSE:INSP) is one of the top NYSE stocks with the highest upside potential. Piper Sandler lo